174 related articles for article (PubMed ID: 7547234)
1. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide].
Evans SM; Joiner B; Jenkins WT; Laughlin KM; Lord EM; Koch CJ
Br J Cancer; 1995 Oct; 72(4):875-82. PubMed ID: 7547234
[TBL] [Abstract][Full Text] [Related]
2. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity.
Koch CJ; Evans SM; Lord EM
Br J Cancer; 1995 Oct; 72(4):869-74. PubMed ID: 7547233
[TBL] [Abstract][Full Text] [Related]
3. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.
Evans SM; Jenkins WT; Joiner B; Lord EM; Koch CJ
Cancer Res; 1996 Jan; 56(2):405-11. PubMed ID: 8542599
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia in human intraperitoneal and extremity sarcomas.
Evans SM; Hahn SM; Magarelli DP; Zhang PJ; Jenkins WT; Fraker DL; Hsi RA; McKenna WG; Koch CJ
Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):587-96. PubMed ID: 11173159
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode.
Jenkins WT; Evans SM; Koch CJ
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):1005-17. PubMed ID: 10705024
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5.
Matthews J; Adomat H; Farrell N; King P; Koch C; Lord E; Palcic B; Poulin N; Sangulin J; Skov K
Br J Cancer Suppl; 1996 Jul; 27():S200-3. PubMed ID: 8763880
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5.
Ziemer LS; Evans SM; Kachur AV; Shuman AL; Cardi CA; Jenkins WT; Karp JS; Alavi A; Dolbier WR; Koch CJ
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):259-66. PubMed ID: 12552344
[TBL] [Abstract][Full Text] [Related]
8. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.
Lee J; Siemann DW; Koch CJ; Lord EM
Int J Cancer; 1996 Jul; 67(3):372-8. PubMed ID: 8707411
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors.
Laughlin KM; Evans SM; Jenkins WT; Tracy M; Chan CY; Lord EM; Koch CJ
J Pharmacol Exp Ther; 1996 May; 277(2):1049-57. PubMed ID: 8627516
[TBL] [Abstract][Full Text] [Related]
10. In vivo colocalization of 2-nitroimidazole EF5 fluorescence intensity and electron paramagnetic resonance oximetry in mouse tumors.
Mahy P; De Bast M; Gallez B; Gueulette J; Koch CJ; Scalliet P; Grégoire V
Radiother Oncol; 2003 Apr; 67(1):53-61. PubMed ID: 12758240
[TBL] [Abstract][Full Text] [Related]
11. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.
Woods ML; Koch CJ; Lord EM
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):93-101. PubMed ID: 12118570
[TBL] [Abstract][Full Text] [Related]
12. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia.
Bergeron M; Evans SM; Sharp FR; Koch CJ; Lord EM; Ferriero DM
Neuroscience; 1999; 89(4):1357-66. PubMed ID: 10362320
[TBL] [Abstract][Full Text] [Related]
13. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.
Lord EM; Harwell L; Koch CJ
Cancer Res; 1993 Dec; 53(23):5721-6. PubMed ID: 8242628
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia in radiation-induced blood-spinal cord barrier breakdown.
Li YQ; Ballinger JR; Nordal RA; Su ZF; Wong CS
Cancer Res; 2001 Apr; 61(8):3348-54. PubMed ID: 11309291
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the concept of "hypoxic fraction" as a descriptor of tumor oxygenation status.
Evans SM; Jenkins WT; Shapiro M; Koch CJ
Adv Exp Med Biol; 1997; 411():215-25. PubMed ID: 9269430
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia is important in the biology and aggression of human glial brain tumors.
Evans SM; Judy KD; Dunphy I; Jenkins WT; Hwang WT; Nelson PT; Lustig RA; Jenkins K; Magarelli DP; Hahn SM; Collins RA; Grady MS; Koch CJ
Clin Cancer Res; 2004 Dec; 10(24):8177-84. PubMed ID: 15623592
[TBL] [Abstract][Full Text] [Related]
19. Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole.
Koch CJ
Radiat Res; 2008 Jun; 169(6):677-88. PubMed ID: 18494550
[TBL] [Abstract][Full Text] [Related]
20. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
